EXACT Sciences (EXAS) Names John Bakewell Chief Financial Officer

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS) today announced the appointment of John K. Bakewell as chief financial officer. Mr. Bakewell will begin his new role on January 1, 2016.

"John brings significant industry and public company experience and financial acumen to Exact Sciences," said Kevin T. Conroy, chairman, president and CEO of Exact Sciences.

Suggested Articles

Outgoing BIO Chair John Maraganore and his successor, Jeremy Levin, reflected on drug pricing, its drivers and its place in the innovation ecosystem.

The study is assessing the effect of the oral AXL inhibitor when given to elderly AML patients in combination with low-intensity chemotherapy.

The proportion of patients who had a greater than 1 g/dL increase in hemoglobin is down on GBT’s prior update but still superior to placebo.